Surrogate end points in cardio-thoracic trials: a call for better reporting and improved interpretation of trial findings

Evidence to inform regulatory, funding and clinical decisions about health interventions should come from well-conducted clinical trials. Despite the challenges associated to their design, conduct and generalizability, randomized controlled trials (RCTs) are typically considered the studies providing the least biased estimates of treatment effects